Bexarotene plus Erlotinib Suppresses Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models

The rexinoid bexarotene represses cyclin D1 by causing its proteasomal degradation. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib represses cyclin D1 via different mechanisms. We conducted a preclinical study and two clinical/translational trials (a window-of-...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer prevention research (Philadelphia, Pa.) Pa.), 2011-06, Vol.4 (6), p.818-828
Hauptverfasser:	Dragnev, Konstantin H., Ma, Tian, Cyrus, Jobin, Galimberti, Fabrizio, Memoli, Vincent, Busch, Alexander M., Tsongalis, Gregory J., Seltzer, Marc, Johnstone, David, Erkmen, Cherie P., Nugent, William, Rigas, James R., Liu, Xi, Freemantle, Sarah, Kurie, Jonathan M., Waxman, Samuel, Dmitrovsky, Ethan
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!